East Rutherford, NJ - January 7, 2013 - Cambrex Corporation (NYSE: CBM, "Cambrex") will be exhibiting its small molecule API products and services designed to accelerate the commercialization of finished drug products at InformexUSA 2013, February 20-22 in Anaheim, CA. In addition, Cambrex will be presenting at the Informex Exhibitor Showcase on February 19.
Cambrex will be showcasing its custom development and manufacturing capabilities including analytical development, process validation and finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, chiral compounds, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, as well as advanced pharmaceutical intermediates.
During the Informex Exhibitor Showcase, Dr. John Michnick will discuss Cambrex's high potency and ultra high potency development and manufacturing capabilities. Cambrex's high potency development center provides containment and rigorous controls to reliably and safely develop and manufacture a wide range of high potency APIs and intermediates, including oncologics and controlled substances.
Cambrex is exhibiting at booth 1523 in the Anaheim Convention Center during InformexUSA.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.
Contact: Stephanie Harrison
Phone: +1 201.804.3061